Archief

R2810-ONC-ISA-1981

17 februari 2022

A Phase 2 Study of Cemiplimab, an Anti-PD-1 Monoclonal Antibody, and ISA101b Vaccine in Patients with Recurrent/Metastatic HPV16 Cervical Cancer who have Experienced Disease Progression after ≥First Line…

HER2CLIMB-02

6 september 2021

Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer Protocolnummer: SGNTUC-016 Eudractnummer:…

Destiny-PanTumor02

15 juni 2021

A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02) Protocolnummer D967VC00001…

M15-913

12 april 2021

An Open Label Phase 1, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects with Previously-Treated Solid Tumors and Hematologic Malignancies. M15-913 Protocolnummer: M15-913 Eudract nummer: 2016-003887-37 METc…

EORTC 1403 / rEECur

International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma Eudractnummer: 2014-000259-99 Dit is een prospectief, multicenter, gerandomiseerd en open-label fase II/fase…

Sunniforecast

A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Standard of Care in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal…

IMPACT-RCC

Watchful waiting in patients with good and intermediate risk metastatic renal cell carcinoma; an imaging guided observational approach. METcnummer: 2014.176 Onderzoekscode: O126 Samenvatting In een deel van de…

CA209-901

A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer (CheckMate 901:…

ICRA

ICRA (Improve Checkpoint-blockade Response in Advanced urothelial cancer), an adaptive clinical study to determine efficacy of combining weekly paclitaxel with tremelimumab +/- durvalumab (MEDI4736) Protocolnummer: ESR-18-13667 EudraCT nummer:…

CA017-078

A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy with Nivolumab or Nivolumab…

Vascular fingerprint

Vascular fingerprint to identify patients at risk for arterial cardiovascular events within the first year after start of cisplatin-based chemotherapy for testicular cancer: a validation study. METc nummer:…

KO-TIP-007

The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS…

ImaGelato

Can 89Zr-atezolizumab PET scan identify patients with metastatic invasive lobular breast cancer who will respond to chemotherapy-immune checkpoint inhibition? ImaGelato Protocolnummer: 201900180 Eudractnummer: 2019-001197-28 METc nummer: 2019/232 Onderzoekscode:…

SONIA

Endocrine therapy plus CDK 4/6 inhibition in first or second line for hormone receptor positive advanced breast cancer. SONIA. Eudract nummer: 2017-002334-23 METc nummer: 2018/351 Samenvatting Het belangrijkste…

SONImage

Samenvatting Deze studie is een zijstudie van de SONIA studie en is binnen deze studie één van de studies waarin biomarkers worden onderzocht. Biomarkers zijn biologische kenmerken die…

GELATO

Een onderzoek naar de veiligheid en werkzaamheid van de behandeling met carboplatin en atezolizumab bij patiënten met uitgezaaide lobulaire borstkanker – de GELATO studie. Protocolnummer: Eudractnummer: 2017-001428-23 METc…